AURXOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. is a U.S.-based commercial-stage medical device company focused on chronic wound care. Its core product is Aurix, an autologous cell-based therapy platform used in wound healing settings, supported by related centrifuge devices, packaging, and distribution arrangements.

Kysy yhtiöstä
Liikevaihto3,3milj. USD
+142,7 %v/v
Liikevoitto (EBIT)−2,5milj. USD
−2,4 %v/v
EBIT-marginaali−76,0%
+104,1 %-yks.v/v
Nettotulos−2,5milj. USD
−8,1 %v/v
Vapaa kassavirta−1,1milj. USD
+52,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−4−2024milj. USD2020: 0,00 milj. USD2020: EBIT −0,38 milj. USD20202021: 0,00 milj. USD2021: EBIT −0,09 milj. USD20212022: 0,11 milj. USD2022: EBIT −3,3 milj. USD20222023: 0,61 milj. USD2023: EBIT −3,2 milj. USD20232024: 1,4 milj. USD2024: EBIT −2,5 milj. USD20242025: 3,3 milj. USD2025: EBIT −2,5 milj. USD20253,3−2,5
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Nuo Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Aurix branded product70 %

The company's own branded autologous wound care product sold through its sales network.

Private label product15 %

Aurix supplied under Smith+Nephew's private label for U.S. distribution.

License and distribution fees7 %

Upfront and ongoing fees tied to the Smith+Nephew distribution agreement.

Centrifuge devices and related supplies8 %

Devices and supporting items used to prepare or deliver the Aurix therapy.

Tuotteet

Raportoitu · osuus liikevaihdosta
93,2%FY2025100 %
  • Products93,2 %
  • License6,8 %

Lähde: 10-Q FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Nuo sells primarily to wound care providers, especially hospital outpatient wound care clinics and related clinical settings. Its customers also include third-party sales representatives, distributors, and a large strategic partner, Smith+Nephew, which purchases private label product and acts as an interim sales agent for certain Aurix-branded sales.

Hospital outpatient wound care clinics

Buy Aurix for chronic wound treatment and clinical use after internal evaluation and reimbursement alignment.

Wound care providers

Clinics and providers that purchase the product to treat complex chronic wounds in outpatient settings.

Smith+Nephew

Purchases private label Aurix product and supports distribution of Aurix-branded product to its customers.

Sales agents and distributors

Third-party representatives that help generate orders and expand commercial coverage across U.S. markets.

Hospital value analysis committees

Evaluate the product for clinical adoption and purchasing approval within hospital systems.

Strategia

Nuo's strategy is to expand adoption of Aurix in chronic wound care by building relationships with wound care providers and hospital systems. It is also using a strategic distribution relationship with Smith+Nephew to broaden market access while continuing to sell its own branded product.

Expand U.S. commercial coverageLyhyt aikaväli

Broader field coverage should increase awareness and access to Aurix among wound care providers.

Drive hospital adoption and reimbursement supportLyhyt aikaväli

Clinical approval and reimbursement execution are necessary for routine use in outpatient wound care.

Leverage Smith+Nephew distributionKeskipitkä aikaväli

The partnership can extend reach and add a second commercialization channel for Aurix.

Maantiede

Nuo is centered on the United States, where it commercializes Aurix and builds its sales network. Its commercial footprint is concentrated in U.S. wound care markets, including multiple large western markets through a multi-state agreement with Pacific Medical, Inc. The company does not disclose meaningful non-U.S. revenue in the provided excerpts.

Riskit

Nuo depends on successful reimbursement, clinical adoption, and execution by a relatively small commercial organization, which makes revenue growth sensitive to payer and provider acceptance. The company also faces product, distribution, and supply-chain risks tied to manufacturing, transfer pricing, and partner execution, especially under the Smith+Nephew arrangement.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Manufacturing and supply-chain risk3Partner concentration risk4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Reimbursement and coverage dependenceVaikutus: Korkea

    Aurix adoption relies on Medicare contractor administration and payer acceptance in wound care.

    Kohdistuu: U.S. hospital outpatient wound care

  2. Commercial adoption riskVaikutus: Korkea

    Hospitals and clinics must approve the product through value analysis and clinical review before broad use.

    Kohdistuu: Hospital outpatient wound care clinics

  3. Manufacturing and supply-chain riskVaikutus: KeskitasoTodennäköisyys: Korkea

    The company must manufacture, package, and ship product on time and at agreed transfer prices.

    Kohdistuu: Private label product and centrifuge devices

  4. Partner concentration riskVaikutus: KeskitasoTodennäköisyys: Matala

    Smith+Nephew is an important distribution partner and private label customer.

    Kohdistuu: U.S. private label distribution

Kysy Clarifolta: Nuo Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Deferred revenue from Smith+Nephew upfront fee

The $1.5 million fee is recognized over five years, affecting reported revenue timing.

Vaikutus: Smooths revenue recognition versus cash receipt

Product revenue recognition

Aurix and private label product sales are recognized when control transfers, creating quarter-to-quarter variability.

Vaikutus: Impacts reported sales growth and gross profit

Inventory and device cost accounting

Centrifuge device purchases and transfer pricing influence gross margin and inventory balances.

Vaikutus: Affects cost of goods sold and margin profile

Commission and fulfillment expense accruals

Sales-agent commissions and packaging/shipping costs rise with commercial activity.

Vaikutus: Affects operating expense timing and comparability

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Nu-Med Plus, Inc.

NUMD · Surgical & Medical Instruments & Apparatus

Smith & Nephew SNATS, Inc

SNN · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Nu Skin Enterprises, Inc

NUS · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Nu Holdings Ltd.

NU · Finance Services

Neuphoria Therapeutics Inc.

NEUP · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Nuo Therapeutics, Inc. (OTC) – Surgical & Medical Instruments & Apparat | Analyysi – Clarifo